Abeona Therapeutics (NASDAQ: ABEO) and Celldex Therapeutics (NASDAQ:CLDX) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, institutional ownership and profitability.
Valuation and Earnings
This table compares Abeona Therapeutics and Celldex Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Abeona Therapeutics||$890,000.00||767.40||-$21.87 million||($0.65)||-22.46|
|Celldex Therapeutics||$6.79 million||55.28||-$128.53 million||($1.01)||-2.73|
Insider and Institutional Ownership
42.0% of Abeona Therapeutics shares are held by institutional investors. Comparatively, 52.5% of Celldex Therapeutics shares are held by institutional investors. 6.8% of Abeona Therapeutics shares are held by insiders. Comparatively, 4.1% of Celldex Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Risk and Volatility
Abeona Therapeutics has a beta of 2.34, meaning that its stock price is 134% more volatile than the S&P 500. Comparatively, Celldex Therapeutics has a beta of 2.73, meaning that its stock price is 173% more volatile than the S&P 500.
This table compares Abeona Therapeutics and Celldex Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of recent ratings for Abeona Therapeutics and Celldex Therapeutics, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Abeona Therapeutics currently has a consensus target price of $27.00, indicating a potential upside of 84.93%. Celldex Therapeutics has a consensus target price of $8.13, indicating a potential upside of 194.38%. Given Celldex Therapeutics’ higher probable upside, analysts plainly believe Celldex Therapeutics is more favorable than Abeona Therapeutics.
Abeona Therapeutics beats Celldex Therapeutics on 8 of the 14 factors compared between the two stocks.
Abeona Therapeutics Company Profile
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB). It is also developing ABO-101 (AAV-NAGLU) for Sanfilippo syndrome type B (MPS IIIB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for epidermolysis bullosa, ABO-301 (AAV-FANCC) for Fanconi anemia disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. The Company also has a plasma-based protein therapy pipeline, including alpha-1 protease inhibitor (SDF Alpha) for inherited COPD, using its proprietary Salt Diafiltration ethanol-free process.
Celldex Therapeutics Company Profile
Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients. Its Glembatumumab vedotin (also referred to as CDX-011) is meant for the treatment of metastatic melanoma. Its Varlilumab (also referred to as CDX-1127) is an immune modulating antibody. Its earlier stage drug candidates in clinical development include CDX-1401, which is a targeted immunotherapeutic aimed at antigen presenting cells (APC) for cancer indications and CDX-301, which is an immune cell mobilizing agent and dendritic cell growth factor. It includes a multi-faceted tumor-associated macrophage (TAM) program. The Company’s pipeline also includes CDX-0158 and CDX-3379, which are humanized monoclonal antibodies.
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.